title: Effect-site concentration of propofol for reduction of remifentanil-induced cough.
abstract: This study examined the effectiveness of different propofol infusion target concentrations on cough suppression, during a target-controlled remifentanil infusion. Four hundred patients were randomly assigned to receive propofol target effect-site concentrations of 0, 3.0, 4.5, or 6.0 microgxml(-1). When the propofol effect-site concentration reached the target, remifentanil was administered at a target effect-site concentration of 4.0 ngxml(-1). Episodes of cough were recorded over a 2-min period after remifentanil commencement, and graded as mild (1-2), moderate (3-4), or severe (5 or more). The overall incidence of cough was significantly decreased in by propofol 6.0 microgxml(-1) compared with 0 or 3.0 microgxml(-1) propofol (p < 0.001). The incidence of severe cough was significantly lower with propofol 6.0 microgxml(-1) compared with 3.0 microgxml(-1) (p = 0.03). A propofol target effect-site concentration of 6.0 microgxml(-1) effectively suppressed remifentanil-induced cough when remifentanil was administrated at a target effect-site concentration of 4.0 ngxml(-1).
authors.affiliation: Department of Anaesthesiology and Pain Medicine, Ajou University School of Medicine, Suwon, Korea.
authors.forename: J Y
authors.initials: JY
authors.lastname: Kim
authors.forename: S Y
authors.initials: SY
authors.lastname: Lee
authors.forename: D H
authors.initials: DH
authors.lastname: Kim
authors.forename: S K
authors.initials: SK
authors.lastname: Park
authors.forename: S K
authors.initials: SK
authors.lastname: Min
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000768:Anesthesia, General / Q000379:methods; D018686:Anesthetics, Intravenous / Q000008:administration & dosage* / Q000009:adverse effects* / Q000097:blood; D001794:Blood Pressure / Q000187:drug effects; D003371:Cough / Q000097:blood / Q000139:chemically induced / Q000517:prevention & control*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D008875:Middle Aged; D010100:Oxygen / Q000097:blood; D010313:Partial Pressure; D010880:Piperidines / Q000009:adverse effects* / Q000097:blood; D015742:Propofol / Q000008:administration & dosage*; D000077208:Remifentanil; D012720:Severity of Illness Index; D055815:Young Adult
chemical_list: D018686:Anesthetics, Intravenous; D010880:Piperidines; D000077208:Remifentanil; D010100:Oxygen; D015742:Propofol